160 related articles for article (PubMed ID: 36114412)
1. Evaluation of lung toxicity with bevacizumab using the spontaneous reporting database.
Kanbayashi Y; Uchida M; Kashiwagi M; Akiba H; Shimizu T
Sci Rep; 2022 Sep; 12(1):15619. PubMed ID: 36114412
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database.
Kanbayashi Y; Uchida M; Kashiwagi M; Akiba H; Shimizu T
Med Oncol; 2022 Sep; 39(12):219. PubMed ID: 36175697
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Time to Onset and Outcome of Lung Adverse Events Related to Pembrolizumab Using Marketing Surveillance.
Kanbayashi Y; Kobayashi M; Anzai M; Shimizu T; Uchida M
Oncology; 2023; 101(12):817-821. PubMed ID: 37591211
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan.
Kanbayashi Y; Shimizu T; Kojima A; Anzai M; Kawai R; Uchida M
Sci Rep; 2023 May; 13(1):8819. PubMed ID: 37258564
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of Bortezomib-Induced Adverse Events Using the Japanese Real-World Database.
Satoki A; Uchida M; Fujiwara M; Uesawa Y; Shimizu T
Oncology; 2022; 100(3):188-194. PubMed ID: 34915520
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Time to Onset and Outcome of Cardiac Adverse Events Associated with Nilotinib using Post-Marketing Surveillance.
Kanbayashi Y; Kojima A; Wakabayashi H; Shimizu T; Uchida M
Oncology; 2023; 101(12):799-807. PubMed ID: 37598671
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Cardiac Adverse Events with Ponatinib Using a Spontaneous Reporting Database.
Kanbayashi Y; Uchida M; Nakano K; Wakabayashi H; Shimizu T
Oncology; 2023; 101(6):397-405. PubMed ID: 37075717
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Time-to-onset and Outcome of Lung Adverse Events With Pomalidomide from a Pharmacovigilance Study.
Kawahara Y; Murata S; Shimizu T; Uesawa Y; Uchida M
In Vivo; 2023; 37(2):955-961. PubMed ID: 36881059
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Cardiac Adverse Events with Nivolumab Using a Japanese Real-World Database.
Kanbayashi Y; Shimizu T; Anzai M; Kawai R; Uchida M
Clin Drug Investig; 2023 Mar; 43(3):177-184. PubMed ID: 36780109
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of everolimus-induced adverse events using the Japanese real-world database.
Uchida M; Nakano K; Fujiwara M; Uesawa Y; Shimizu T
J Clin Pharm Ther; 2022 Aug; 47(8):1173-1180. PubMed ID: 35316861
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of thromboembolic events in cancer patients receiving bevacizumab according to the Japanese Adverse Drug Event Report database.
Matsumura C; Chisaki Y; Sakimoto S; Sakae H; Yano Y
J Oncol Pharm Pract; 2018 Jan; 24(1):22-27. PubMed ID: 27856923
[TBL] [Abstract][Full Text] [Related]
12. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
Nagai J; Ishikawa Y
PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Durvalumab-induced Lung Toxicity Using a Spontaneous Reporting Database.
Anticancer Res; ; . PubMed ID: 35790278
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]